242 related articles for article (PubMed ID: 9661792)
1. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
Maksimenko AV
Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
[TBL] [Abstract][Full Text] [Related]
2. New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.
Maksimenko AV; Tischenko EG
J Thromb Thrombolysis; 1999 Jun; 7(3):307-12. PubMed ID: 10373713
[TBL] [Abstract][Full Text] [Related]
3. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
Collen D
Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
[No Abstract] [Full Text] [Related]
4. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
Collen D; Stassen JM; De Cock F
Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
[TBL] [Abstract][Full Text] [Related]
5. Thrombolytic effect after sequential double-bolus administration of tissue plasminogen activator and urokinase-fibrinogen conjugate into dogs with venous thrombosis.
Maksimenko AV; Tischenko EG; Golubykh VL
Ann N Y Acad Sci; 1998 Dec; 864():409-17. PubMed ID: 9928118
[No Abstract] [Full Text] [Related]
6. [Effects of potentiation and rapid action in models of venous thrombosis in dogs upon combined administration of the plasminogen tissue activator and urokinase modified by fibrinogen].
Maksimenko AV; Tishchenko EG; Petrova ML; Golubykh VL
Biull Eksp Biol Med; 1996 Jan; 121(1):48-51. PubMed ID: 8680005
[No Abstract] [Full Text] [Related]
7. Potentiation by heparin fragment CY 222 (Choay) of thrombolysis induced by human tissue-type plasminogen activator.
Juhan-Vague I; Stassen JM; Alessi MC; Elias A; Aillaud MF; Serradimigni A; Collen D
Semin Thromb Hemost; 1989 Oct; 15(4):390-4. PubMed ID: 2554499
[No Abstract] [Full Text] [Related]
8. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
Gurewich V; Pannell R
Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
[No Abstract] [Full Text] [Related]
9. Importance of fibrin specificity in therapeutic thrombolysis and the rationale of using sequential and synergistic combinations of tissue plasminogen activator and pro-urokinase.
Gurewich V
Semin Thromb Hemost; 1989 Apr; 15(2):123-8. PubMed ID: 2501871
[No Abstract] [Full Text] [Related]
10. Fibrinolytic agents: mechanisms of activity and pharmacology.
Lijnen HR; Collen D
Thromb Haemost; 1995 Jul; 74(1):387-90. PubMed ID: 8578491
[TBL] [Abstract][Full Text] [Related]
11. Serine-proteases as plasminogen activators in terms of fibrinolysis.
Flemmig M; Melzig MF
J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
[TBL] [Abstract][Full Text] [Related]
12. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolytic agents.
Schmitz-Huebner U; van de Loo J
Clin Haematol; 1981 Jun; 10(2):481-96. PubMed ID: 7032785
[No Abstract] [Full Text] [Related]
14. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
Veremeenko KN; Kizim AI
Vopr Med Khim; 1984; 30(5):13-22. PubMed ID: 6084892
[TBL] [Abstract][Full Text] [Related]
15. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
Spriggs DJ; Stassen JM; Hashimoto Y; Collen D
Blood; 1989 Apr; 73(5):1207-12. PubMed ID: 2495034
[TBL] [Abstract][Full Text] [Related]
16. The search for the ideal thrombolytic agent.
Verstraete M
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):4B-10B. PubMed ID: 2959714
[TBL] [Abstract][Full Text] [Related]
17. New strategy of thrombolysis. Conjunctive effect of plasminogen activators with different pharmacokinetic profile.
Maksimenko AV
Ann N Y Acad Sci; 1998 Dec; 864():96-105. PubMed ID: 9928084
[TBL] [Abstract][Full Text] [Related]
18. [Thrombolysis using tissue-type plasminogen activator and pro-urokinase: synergism; mutants and hybrids].
Páramo JA; Fernández FJ; Cuesta B; Paloma MJ; Rocha E
Sangre (Barc); 1989 Aug; 34(4):297-9. PubMed ID: 2505395
[No Abstract] [Full Text] [Related]
19. Molecular mechanism of action of newer thrombolytic agents.
Collen D
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
[TBL] [Abstract][Full Text] [Related]
20. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy.
Conard J; Samama MM
Semin Thromb Hemost; 1987 Apr; 13(2):212-22. PubMed ID: 3114887
[No Abstract] [Full Text] [Related]
[Next] [New Search]
